VR VRTX Vertex Pharmaceuticals Loading... : Bullish and Bearish Analyst Opinions

Goldman Sachs updates its monthly Director's Cut list by adding Vertex Pharmaceuticals.

Author is long VERA ahead of eGFR readout, arguing interim data and longer follow-up support.

New purchase as healthcare allocation increases.

RBC lowered its price target for Vertex Pharmaceuticals to 570 dollars from 577 dollars.

TD Cowen raised its price target for Vertex Pharmaceuticals to 550 dollars from 525 dollars.

Vertex raised full-year revenue guidance, driven by strong performance across CF, Casgevi, and Journavix, despite headwinds from FX and product mix.

Vertex Pharmaceuticals reported Q2 revenue above estimates with adjusted EPS in line and raised.

Vertex Pharmaceuticals reports second quarter revenue and adjusted EPS in line with estimates.

Data center solutions backlog is growing ahead of expectations, leading to confidence in a >$2 billion annualized exit run rate by 2027. — Signals accelerating demand for modular data center infrastructure, potentially straining supply chains and benefiting peers like Vertiv.

The tweet details the merger negotiation timeline between Vertex and Crinetics without.

Vertex acquisition diversifies product line.

Vertex Pharmaceuticals is reportedly acquiring Crinetics Pharmaceuticals for $10 billion.

The author dismisses VRTX as a potential buyer of ABVX but suggests M&A capital could rotate.

Author reflects on selling CRNX too soon before its Vertex acquisition, praises XBI strength.

The author congratulates CRNX longs on a premium deal and highlights Vertex and the biotech ETF.

Author speculates about ABVX moving earnings and potential buyout or data release.

Management's guidance tone is positive, with reiterated revenue targets and strong launch momentum across non-CF products (Casgevi, Journavix), indicating a healthy growth trajectory.

Biogen notes Vertex as a competitor recruiting in the nephrology space, indicating a competitive hiring and clinical trial landscape.

Vertex Pharmaceuticals is a good buy.

"The biotech company said its drug to treat a kidney disorder met its goal in a late stage trial, providing a boost to its strategy of moving beyond cystic fibrosis treatments." Successfully diversifying its pipeline beyond its core cystic fibrosis franchise removes a massive long-term growth overhang. With an estimated $5 billion in peak sales for this new drug, the company's addressable market expands significantly, justifying a higher valuation multiple. LONG. The clinical success de-risks the company's 2026 outlook and proves their R&D engine can produce blockbuster drugs outside of their legacy niche. Regulatory hurdles during the FDA approval process or slower-than-expected commercial adoption once launched.

Companies that spend heavily on lobbying Washington consistently outperform the S&P 500. In a world where 52% of S&P companies list "Government" as a top risk, those who pay to be at the table (Lobbying Intensity) protect their moats and influence regulation in their favor. Long the "Lobbying Intensity" factor (e.g., Eli Lilly, Meta, Vertex). Populist backlash banning corporate lobbying.

Oz explicitly mentions "CRISPR technology" and states CMS is willing to pay for "drugs... that can cure, not just treat, Sickle Cell Anemia." He cites a cost of "$2 million" but notes it saves the system "$10 million." The primary bear case for gene editing stocks (like CRISPR Therapeutics, Vertex, and bluebird bio) is the fear that insurers/government won't pay the massive upfront price tags. The CMS Administrator confirming they are "banking on these technologies" and will "pay for them when they get there" removes the single biggest overhang for the sector. LONG. Government backing guarantees a market for these high-ticket curative therapies. Clinical trial failures or safety issues with the specific therapies.

Vertex is guiding to 8-9% total revenue growth, with management expressing strong confidence in the ramp of non-CF products (Casgevi and Journavix) to contribute $500M+ in 2026, indicating a positive medium-term outlook.